Unlocking the therapeutic potential of edible mushrooms: Ganoderma and their secondary metabolites as novel antiviral agents for combating COVID-19 DOI
Samantha C. Karunarathna, Wenhua Lu,

Nimesha Patabedige

et al.

New Zealand Journal of Botany, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 59

Published: Aug. 8, 2024

The global COVID-19 pandemic, caused by SARS-CoV-2, has created an urgent need for novel antiviral agents, as it led to a devastating loss of lives worldwide. In response, numerous vaccines were developed in 2022, with ongoing efforts more candidates. Despite significant progress, reports vaccine-related issues and side effects have emerged. effectiveness been challenged new viral variants, lack well-designed vivo experiments, randomised controlled trials. Currently, no clinically approved medications exist treating COVID-19. However, few broad-spectrum drugs shown promising outcomes clinical studies. Many scientists believe that natural compounds derived from herbal medicines mushrooms could offer substantial benefits patients. Ganoderma, known its traditional use promoting health longevity, rich history therapeutic applications dietary supplementation. Numerous epidemiological studies demonstrated Ganoderma derivatives can enhance innate adaptive immune responses against various pathogens, including viruses, laboratory settings living organisms. Therefore, the secondary metabolites such triterpenoids, polysaccharides, glycoproteins, hold potential developing drugs. These mechanisms, inhibition replication, modulation responses, direct virucidal effects. Given search effective treatments COVID-19, bioactive stand out candidates further research development. Their multifaceted mechanisms make them suitable exploration agents potentially contributing enhancing existing treatments.

Language: Английский

Unlocking the therapeutic potential of edible mushrooms: Ganoderma and their secondary metabolites as novel antiviral agents for combating COVID-19 DOI
Samantha C. Karunarathna, Wenhua Lu,

Nimesha Patabedige

et al.

New Zealand Journal of Botany, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 59

Published: Aug. 8, 2024

The global COVID-19 pandemic, caused by SARS-CoV-2, has created an urgent need for novel antiviral agents, as it led to a devastating loss of lives worldwide. In response, numerous vaccines were developed in 2022, with ongoing efforts more candidates. Despite significant progress, reports vaccine-related issues and side effects have emerged. effectiveness been challenged new viral variants, lack well-designed vivo experiments, randomised controlled trials. Currently, no clinically approved medications exist treating COVID-19. However, few broad-spectrum drugs shown promising outcomes clinical studies. Many scientists believe that natural compounds derived from herbal medicines mushrooms could offer substantial benefits patients. Ganoderma, known its traditional use promoting health longevity, rich history therapeutic applications dietary supplementation. Numerous epidemiological studies demonstrated Ganoderma derivatives can enhance innate adaptive immune responses against various pathogens, including viruses, laboratory settings living organisms. Therefore, the secondary metabolites such triterpenoids, polysaccharides, glycoproteins, hold potential developing drugs. These mechanisms, inhibition replication, modulation responses, direct virucidal effects. Given search effective treatments COVID-19, bioactive stand out candidates further research development. Their multifaceted mechanisms make them suitable exploration agents potentially contributing enhancing existing treatments.

Language: Английский

Citations

1